TNGX
Tango Therapeutics, Inc.
Latest Form 4:Sale$736KbyCrystal Adam (President, R&D) · filed Aug 5, 2026
Tango Therapeutics, Inc. (TNGX) has 25 SEC Form 4 filings (43 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Aug 5, 2026.
The most active filer is President, R&D Crystal Adam with 10 filings. Insiders have net sold $5.5M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Malte Peters
- Employees:137
- HQ:Boston, MA, US
- IPO:2020-09-03
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$22.7M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$3.9B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| President, R&D | Sale | 27,000 | $736K | Aug 5 | SEC ↗ | |
| President, R&D | Sale | 27,000 | $799K | Jul 2 | SEC ↗ | |
| President, R&D | Sale | 27,000 | $618K | Jun 3 | SEC ↗ | |
| President, R&D | Sale | 27,000 | $573K | May 5 | SEC ↗ | |
| President, R&D | Sale | 38,460 | $962K | Apr 16 | SEC ↗ | |
| President, R&D | Sale | 27,000 | $572K | Apr 2 | SEC ↗ | |
| President, R&D | Sale | 12,000 | $241K | Mar 27 | SEC ↗ | |
| President, R&D | Sale | 20,251 | $304K | Mar 9 | SEC ↗ | |
| President, R&D | Sale | 54,345 | $694K | Feb 27 | SEC ↗ | |
Weber BarbaraFirst filing | Director, Executive Chair | Sale | 30,519 | $374K | Feb 4 | SEC ↗ |
Beckman DaniellaFirst filing | Chief Financial Officer | Sale | 10,317 | $127K | Feb 4 | SEC ↗ |
Crystal AdamFirst filing | President, R&D | Sale | 18,452 | $226K | Feb 4 | SEC ↗ |
| 10% Owner | Sale | 477,401 | $4.8M | Oct 27 | SEC ↗ | |
| 10% Owner | Sale | 500,000 | $4.0M | Sep 29 | SEC ↗ | |
| 10% Owner | Sale | 363,541 | $2.6M | Sep 17 | SEC ↗ | |
Third Rock Ventures IV, L.P.First filing | 10% Owner | Sale | 642,906 | $4.5M | Sep 9 | SEC ↗ |
Third Rock Ventures IV, L.P.First filing | 10% Owner | Sale | 86,459 | $609K | Sep 9 | SEC ↗ |
Related companies
Tango Therapeutics, Inc. is in the Healthcare sector.